Evidence map›Paper›PMID 33752759›Full record

ArticlePilot and feasibility studies2021

The impact of sleep disorders on microvascular complications in patients with type 2 diabetes (SLEEP T2D): the protocol of a cohort study and feasibility randomised control trial.

Christina Antza, Ryan Ottridge, Smitaa Patel, Gemma Slinn, Sarah Tearne, Matthew Nicholls, Brendan Cooper, Asad Ali, Abd A Tahrani

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pilot and feasibility studies, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. The impact of obstructive sleep apnea treatment on microvascular complications in patients with type 2 diabetes: a feasibility randomized controlled trial.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2024
    Trial
  2. Association between sleep duration and obesity in patients with type 2 diabetes: A longitudinal study.Diabetic medicine : a journal of the British Diabetic Association · 2025
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Christina AntzaInstitute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.
Ryan OttridgeBirmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Smitaa PatelBirmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Gemma SlinnBirmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Sarah TearneBirmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Matthew NichollsInstitute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.
Brendan CooperLung Function & Sleep, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Asad AliDepartment of Respiratory Medicine, University Hospitals Coventry & Warwickshire, Coventry, UK.
Abd A TahraniInstitute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK. A.A.Tahrani@bham.ac.uk.ORCID http://orcid.org/0000-0001-9037-1937
University of Birmingham · GBUniversity Hospitals Birmingham NHS Foundation Trust · GBUniversity Hospitals Coventry and Warwickshire NHS Trust · GB

Funding

National Institute for Health Research CS-2013-13-029
6 · The paper itself

Abstract

backgroundObstructive sleep apnoea (OSA) is very common in patients with type 2 diabetes (T2D). We and others have shown that OSA was associated with diabetes-related microvascular complications in patients with T2D in cross-sectional and longitudinal studies and that compliance with continuous positive airway pressure (CPAP) reduced the progression of microvascular complications. Hence, we hypothesised that adequate CPAP reduces the development of microvascular complication in patients with T2D.

methodsSLEEP T2D is a cohort study with embedded feasibility, open-label, parallel-arm, randomised control trial (RCT) over 2 years. The primary aim is the feasibility of conducting a definitive RCT assessing the impact of CPAP on chronic kidney disease and other microvascular complications in patients with T2D. The main parameters are to assess willingness of participants to be randomised, follow-up rates, CPAP adherence/compliance, to optimise the choice of outcome measures for a substantive trial, and to identify the parameters for sample size calculations. The secondary aims of the study are related to the impact of CPAP, sleep-related disorders, and sleep chronotype on a variety of diabetes-related end points. The study participants were recruited from the T2D services in multiple NHS trusts across England. The main exclusion criteria for the cohort study are as follows: T1D, eGFR < 15 mL/min/1.73 m DISCUSSION: The feasibility RCT will help us design the future RCT to assess the impact of CPAP on diabetes-related microvascular complications. The cohort study will generate preliminary data regarding the impact of sleep quality, duration, and chronotype on diabetes-related outcomes which could lead to further mechanistic and interventional studies.

trial registrationISRCTN, ISRCTN12361838 . Registered 04 April 2018, Protocol version: v5.0 02.12.19.

Indexed as

Chronic kidney diseaseContinuous positive airway pressureDiabetic footNephropathyNeuropathyObstructive sleep apnoeaRandomised control trialRetinopathySight-threatening retinopathyType 2 diabetes mellitus

Identifiers

PMID33752759
PMCPMC7982768
OpenAlexW3137337627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.